Rockwell Medical,Inc. (NASDAQ:RMTI) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On May9, 2017, the Company issued a press release announcing its
financial results for the quarter ended March31, 2017. A
transcript of the related earnings call/webcast held on May9,
2017, discussing its financial results for the quarter ended
March31, 2017, is attached hereto as Exhibit99.2.
Item 9.01. Financial Statements and Exhibits.
The following exhibits are furnished with this Form8-K:
|
Exhibit |
|
Description |
|
99.1 |
Press Release dated May9, 2017 (filed with original Form8-K |
|
|
99.2 |
Earnings Call Transcript dated May9, 2017 (filed herewith) |
About Rockwell Medical, Inc. (NASDAQ:RMTI)
Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients. Rockwell Medical, Inc. (NASDAQ:RMTI) Recent Trading Information
Rockwell Medical, Inc. (NASDAQ:RMTI) closed its last trading session down -0.36 at 7.20 with 204,552 shares trading hands.